CN Patent

CN112920108A — 酒石酸匹莫范色林晶型a的制备方法

Assigned to Beijing Nuokangda Pharmaceutical Technology Co ltd · Expires 2021-06-08 · 5y expired

What this patent protects

本申请涉及药物和化学领域，具体涉及酒石酸匹莫范色林晶型A的制备方法。所述方法包括：将式(I)化合物溶于溶剂中；将所得溶液降温；以及分离得到沉淀固体；其中，所述溶剂为浓度为90.0‑98.5％的乙醇水溶液、90.0‑98.5％的异丙醇水溶液，或90.0‑98.5％的乙醇和异丙醇的混合水溶液。本发明方法可稳定的制备出高纯度的酒石酸匹莫范色林晶型A。

USPTO Abstract

本申请涉及药物和化学领域，具体涉及酒石酸匹莫范色林晶型A的制备方法。所述方法包括：将式(I)化合物溶于溶剂中；将所得溶液降温；以及分离得到沉淀固体；其中，所述溶剂为浓度为90.0‑98.5％的乙醇水溶液、90.0‑98.5％的异丙醇水溶液，或90.0‑98.5％的乙醇和异丙醇的混合水溶液。本发明方法可稳定的制备出高纯度的酒石酸匹莫范色林晶型A。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN112920108A
Jurisdiction: CN
Classification: —
Expires: 2021-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Nuokangda Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.